financetom
Business
financetom
/
Business
/
Engineered wood products maker Louisiana-Pacific Q3 adjusted EPS beats expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Engineered wood products maker Louisiana-Pacific Q3 adjusted EPS beats expectations
Nov 5, 2025 3:40 AM

Overview

* Louisiana-Pacific ( LPX ) Q3 consolidated net sales decreased by $59 mln to $663 mln

* Adjusted EBITDA for Q3 beats analyst expectations

* Adjusted EPS for Q3 missed analyst expectations

Outlook

* Company expects Q4 siding net sales to grow by ~3% to $370 mln

* Louisiana-Pacific ( LPX ) projects full-year siding net sales growth of ~8% to $1.68 bln

* Company estimates full-year capital expenditures at ~$315 mln

Result Drivers

* SIDING SALES - Siding net sales increased by $22 mln, driven by 5% higher selling prices

* OSB DECLINE - OSB net sales decreased by $74 mln due to lower prices and volumes

* ADJUSTED EBITDA IMPACT - Decrease in Adjusted EBITDA primarily due to $55 mln impact from lower OSB prices and $5 mln from lower volumes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $443 mln

Siding

Sales

Q3 Miss $0.36 $0.41

Adjusted (11

EPS Analysts

)

Q3 Beat $82 mln $80.25

Adjusted mln (10

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

* Wall Street's median 12-month price target for Louisiana-Pacific Corp ( LPX ) is $111.00, about 23.1% above its November 4 closing price of $85.33

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enbridge to build pipelines to service BP's Kaskida oil hub
Enbridge to build pipelines to service BP's Kaskida oil hub
Oct 3, 2024
Oct 3 (Reuters) - Enbridge ( ENB ) said on Thursday it would build and operate crude oil and natural gas pipelines in the U.S. Gulf of Mexico for the recently sanctioned Kaskida oil hub, operated by BP. The pipelines are expected to be operational by 2029 and would cost $700 million, the Canadian firm said. The crude oil pipeline...
AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
Oct 3, 2024
07:18 AM EDT, 10/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that its supplemental new drug application for Calquence, or acalabrutinib, was accepted and granted priority review by the US Food and Drug Administration for the treatment of adults with previously untreated mantle cell lymphoma. The company said it expects the FDA to act on the application in...
International Game Technology Extends Contract with North Carolina Education Lottery for 10 Years
International Game Technology Extends Contract with North Carolina Education Lottery for 10 Years
Oct 3, 2024
07:18 AM EDT, 10/03/2024 (MT Newswires) -- International Game Technology ( IGT ) said Thursday that its subsidiary, IGT Global Solution, has signed a 10-year contract extension with the North Carolina Education Lottery, effective July 1, 2027, through June 2037. Under the agreement, IGT will deploy its Aurora central system, upgrade Wizard back-office business applications, and expand testing capabilities for...
Hims & Hers Health Shares Fall After Weight-Loss Drug Shortage Ends
Hims & Hers Health Shares Fall After Weight-Loss Drug Shortage Ends
Oct 3, 2024
07:19 AM EDT, 10/03/2024 (MT Newswires) -- Hims & Hers Health ( HIMS ) shares fell by nearly 9% in Thursday's premarket activity a day after the US Food and Drug Administration said that a shortage of tirzepatide injection medication has been resolved. The FDA said the weight-loss drug has been in short supply since 2022 due to increased demand....
Copyright 2023-2026 - www.financetom.com All Rights Reserved